IOVA Iovance Biotherapeutics, Inc.
IOVA Iovance Biotherapeutics, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-10-23 1 bull converging
POC $3.74 · VWAP $5.09 · +176.8% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
IOVA Price Structure
Loading timeframes…
Peers
Every watchlist IOVA belongs to, members best 30-day change first — IOVA highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Against street estimates
How IOVA's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
News (last pull)
Headlines about IOVA from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 23 days ago · Sep 30
- Iovance Biotherapeutics (IOVA) Shares Surge Over 30% After Raising 2026 Revenue Forecast
- Why Is Iovance Biotherapeutics Stock Surging Today? - Iovance Biotherapeutics (NASDAQ:IOVA) - Benzinga
- Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History - Yahoo Finance
- Iovance Biotherapeutics Earnings Q3 2026 | IOVA News & Analysis
- Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million - BioSpace
IOVA research tape
77 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.